



Expand your research with confidence
BD Horizon™ Human T Cell Backbone Panel
Flexible and pre-optimized for easier panel design

LEARN MORE



The Journal of Immunology

CORRECTION | MARCH 15 2005

Enhanced Tolerance to Autoimmune Uveitis in CD200-Deficient Mice Correlates with a Pronounced Th2 Switch in Response to Antigen Challenge.

FREE

Neil Taylor; ... et. al

J Immunol (2005) 174 (6): 3818.

<https://doi.org/10.4049/jimmunol.174.6.3818-c>

Related Content

Enhanced Tolerance to Autoimmune Uveitis in CD200-Deficient Mice Correlates with a Pronounced Th2 Switch in Response to Antigen Challenge

J Immunol (January,2005)

Recombinant CD200 Protein Does Not Bind Activating Proteins Closely Related to CD200 Receptor

J Immunol (August,2005)

CD200 Expression on Tumor Cells Suppresses Antitumor Immunity: New Approaches to Cancer Immunotherapy

J Immunol (May,2007)

CORRECTIONS

Gundrun Ratzinger, Jan Baggers, Maria A. de Cos, Jianda Yuan, Tao Dao, John L. Reagan, Christian Münz, Glenn Heller, and James W. Young. Mature Human Langerhans Cells Derived from CD34⁺ Hematopoietic Progenitors Stimulate Greater Cytolytic T Lymphocyte Activity in the Absence of Bioactive IL-12p70, by Either Single Peptide Presentation or Cross-Priming, Than Do Dermal-Interstitial or Monocyte-Derived Dendritic Cells. *The Journal of Immunology*, 2004, 173: 2780–2791.

In *Materials and Methods*, in the third sentence of the third paragraph under the heading *Cell purification and generation of DCs* (Fig. 1), an error was made in the cytokine dosage. The dosage for FLT-3 ligand is nanograms per milliliters instead of micrograms per milliliters. The correct sentence is shown below.

Specific cytokine supplements used in common for generating both LCs and DDC-IDCs included GM-CSF (1000 IU/ml), TNF- α (5 ng/ml), *c-kit* ligand (20 ng/ml), and FLT-3 ligand (50 nanograms/ml).


Daisuke Sakurai, Naoyuki Tsuchiya, Akihiro Yamaguchi, Yurai Okaji, Nelson H. Tsuno, Tetsuji Kobata, Koki Takahashi, and Katsushi Tokunaga. Crucial Role of Inhibitor of DNA Binding/Differentiation in the Vascular Endothelial Growth Factor-Induced Activation and Angiogenic Processes of Human Endothelial Cells. *The Journal of Immunology*, 2004, 173: 5801–5809.

In *Materials and Methods*, in the second sentence of the third paragraph under the heading *Endothelial cell culture and transient transfection*, the nucleotide sequence of *ID3* shRNA is incorrect. The correct sequence is shown below.

TCGGATCCAACCACTGCTACTCCCCTGTTCAAGAGACAGGCGGGAGTAGCAGTGGTTTTTTGGAAAA
GCTTGG.

Nathaniel J. Brown, Jack Hutcheson, Emily Bickel, John C. Scatizzi, Lee D. Albee, G. Kenneth Haines III, Joy Eslick, Kathleen Bradley, Elsa Taricone, and Harris Perlman. Fas Death Receptor Signaling Represses Monocyte Numbers and Macrophage Activation In Vivo. *The Journal of Immunology*, 2004, 173: 7584–7593.

In *Results*, the F4/80 B6 panel of Fig. 5A was inadvertently duplicated in the F4/80 *lpr/lpr* panel. The figure legend is correct as originally published and the data and conclusions in the manuscript are not affected. The correct figure is shown below.



Neil Taylor, Karen McConnachie, Claudia Calder, Rosemary Dawson, Andrew Dick, Jonathon D. Sedgwick, and Janet Liversidge. Enhanced Tolerance to Autoimmune Uveitis in CD200-Deficient Mice Correlates with a Pronounced Th2 Switch in Response to Antigen Challenge. *The Journal of Immunology*, 2005, 174: 143–154.

The second author's last name is misspelled. The correct name is Karen McConachie.